References cited
Article section 11 of 12.  Previous  Next

By K K Jain MD

Angehagen M, Ben-Menachem E, Ronnback L, Hansson E. Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate. Neurochem Res 2003;28(2):333-40.

Arroyo S, Boothman BR, Brodie MJ, et al. A randomised open-label study of tiagabine given two or three times daily in refractory epilepsy. Seizure 2005;14(2):81-4.

Bentué-Ferrer D, Tribut O, Verdier MC; le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique. Therapeutic drug monitoring of tiagabine. [Article in French] Therapie 2010;65(1):51-5.

Burstein AH, Boudreau EA, Theodore WH. Increase in tiagabine serum concentration with coadministration of gemfibrozil. Ann Pharmacother 2009;43(2):379-82.

Chu ML, Sala DA. The use of tiagabine in pediatric spasticity management. Dev Med Child Neurol 2006;48(6):456-9.

Connor KM, Davidson JR, Weisler RH, Zhang W, Abraham K. Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology (Berl) 2006;184(1):21-5.

Crawford P, Meinardi H, Brown S, et al. Tiagabine: efficacy and safety in adjunctive treatment of partial seizures. Epilepsia 2001;42(4):531-8.

Davidson JR, Brady K, Mellman TA, et al. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol 2007;27(1):85-8.

Dunlop BW, Papp L, Garlow SJ, et al. Tiagabine for social anxiety disorder. Hum Psychopharmacol 2007;22(4):241-4.

Evans KC, Simon NM, Dougherty DD, et al. A PET study of tiagabine treatment implicates ventral medial prefrontal cortex in generalized social anxiety disorder. Neuropsychopharmacology 2009;34(2):390-8.

Gironell A, Martínez-Corral M, Pagonabarraga X, Kulisevsky J. Tiagabine for essential tremor: an open-label trial. Mov Disord 2008;23(13):1955-6.

Jedrzejczak J. Tiagabine as add-on therapy may be more effective with valproic acid--open label, multicentre study of patients with focal epilepsy. Eur J Neurol 2005;12(3):176-80.

Kalviainen R, Brodie MJ, Duncan J, Chadwick D, Edwards D, Lyby K. A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures. Northern European Tiagabine Study Group. Epilepsy Res 1998;30(1):31-40.

Kast RE. Tiagabine may reduce bruxism and associated temporomandibular joint pain. Anesth Prog 2005;52(3):102-4.

Leikin JB, Benigno J, Dubow JS, Fisher M. Status epilepticus due to tiagabine ingestion. Am J Ther 2008;15(3):290-1.

Pollack MH, Tiller J, Xie F, Trivedi MH. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol 2008;28(3):308-16.

Pushpal D, Shamshul HN. Tiagabine withdrawal-emergent mania. Aust N Z J Psychiatry 2006;40(8):719.

Schwartz TL, Nihalani N. Tiagabine in anxiety disorders. Expert Opin Pharmacother 2006;7(14):1977-87.

Sills GJ. Pre-clinical studies with the GABAergic compounds vigabatrin and tiagabine. Epileptic Disord 2003;5(1):51-6.

Todorov AA, Kolchev CB, Todorov AB. Tiagabine and gabapentin for the management of chronic pain. Clin J Pain 2005;21(4):358-61.

Vollmar C, Noachtar S. Tiagabine-induced myoclonic status epilepticus in a nonepileptic patient. Neurology 2007;68(4):310.

Wang X, Ratnaraj N, Patsalos PN. The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus). Seizure 2004;13(8):574-81.

Winhusen TM, Somoza EC, Harrer JM, et al. A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction 2005;100(Suppl 1):68-77.

Zwanzger P, Eser D, Nothdurfter C, et al. Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder. Pharmacopsychiatry 2009;42(6):266-9.

**References especially recommended by the author or editor for general reading.

In This Article

Historical note and nomenclature
Clinical trials
Goals and duration of treatment
Precautions and use in special groups
Adverse effects
References cited